目录产品 » LY6G6D hFc Chimera, Cynomolgus
Manual
SDS
COAs

LY6G6D hFc Chimera, Cynomolgus

LY6G6D is a selectively expressed colorectal cancer antigen that can be used for targeting a therapeutic T-cell response by a T-cell engager.LY6G6D was identified as a selectively expressed CRC antigen that can be utilized to potently re-direct and activate cytotoxic T-cells to lyse LY6G6D expressing CRC using a TcE. This effect can be spread to target negative neighboring tumor cells, potentially leading to improved therapeutic efficacy.
￥3300
Z04863-100

产品简介
Species Cynomolgus
Protein Construction
hFc LY6G6D (Asn20-Ser104)_x000D_
Accession # XP_014991478.1
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 34.65 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 40-50 kDa based on Bis-Tris PAGE result.
Formulation Supplied as 0.22 μm filtered solution in PBS (pH 7.4).
Concentration Verified by one or more methods from 0.64mg/ml A280/Bioactivity/BCA/Bradford.
Storage & Stability This product remains stable for 6 months at -80°C or below. Avoid repeated freeze-thaw cycles.
返回

技术背景
Target Background LY6G6D is a selectively expressed colorectal cancer antigen that can be used for targeting a therapeutic T-cell response by a T-cell engager.LY6G6D was identified as a selectively expressed CRC antigen that can be utilized to potently re-direct and activate cytotoxic T-cells to lyse LY6G6D expressing CRC using a TcE. This effect can be spread to target negative neighboring tumor cells, potentially leading to improved therapeutic efficacy.
Synonyms Protein Ly6-D; C6orf23; G6D; MEGT1; NG25
返回

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.